Maravai Life Sciences announces cost reduction plan.
Maravai Life Sciences announced on Tuesday a cost reduction plan with an annualized target of $50 million, aiming to achieve positive EBITDA by 2026. The company specifically emphasized its bioprocess safety testing and nucleic acid production business segments.
Latest